References

1. Bienz-Tadmor B, et al. Biopharmaceuticals and Conventional Drugs: Clinical Success Rates. Biotechnol. (NY) 10(5) 1992: 521525.

2. Bienz-Tadmor B. Biopharmaceuticals Go to Market: Patterns of Worldwide DevelopmentNew Drugs Become Available at Different Rates in Different Countries (Who's Ahead and Who's Behind?) Biotechnol. (NY) 11(2) 1993: 168172.

3. Fussenegger M, et al. Genetic Optimization of Recombinant Glycoprotein Production By Mammalian Cells. Trends Biotechnol. 17(1) 1999: 3542.

4. Reichert JM. New Biopharmaceuticals in the USA: Trends in Development and Marketing Approvals 19951999. Trends Biotechnol. 18(9) 2000: 364369.

5. Maggon K. Monoclonal Antibody "Gold Rush." Curr. Med. Chem. 14(18) 2007: 19781987.

6. Morrow KJJ. Antibody Technology Highlighted in Europe. Gen. Eng. News 24(1) 2004: 5257.

7. Walsh G. Biopharmaceutical Benchmarks 2006. Nat. Biotechnol. 24(7) 2006: 769778.

8. Dubel S. Recombinant Therapeutic Antibodies. Appl. Microbiol. Biotechnol. 74 2007: 723729.

9. Ryu JS, et al. Effects of Cloned Gene Dosage on the Response of Recombinant CHO Cells to Hyperosmotic Pressure in Regard to Cell Growth and Antibody Production. Biotechnol. Prog. 17(6) 2001: 993999.

10. Bi JX, Shuttleworth J, Al R. Uncoupling of Cell Growth and Proliferation Results in Enhancement of Productivity in p21CIP1-Arrested CHO Cells. Biotechnol. Bioeng. 85(7) 2004: 741749.

11. Hawley-Nelson P. Antibody Expression Problem: Diagnosis and Improvement Using a Combination of Molecular and Cell Biology. Williamsburg Bioprocessing Conference, 1519 March 2004, Amsterdam, The Netherlands. Williamsburg Bioprocessing Foundation: Virginia Beach, VA; www.wilbio.com.

12. Field RP. Expression of Human Antibodies for Clinical Trail Supply Using Myeloma Cells. Antibody Production and Downstream Processing, October 2002, London, UL. IBC LifeSciences: London, UK; www.ibc-lifesci.com.

13. Barnes LM, Bentley CM, Dickson AJ. Characterization of the Stability of Recombinant Protein Production in the GS-NS0 Expression System. Biotechnol. Bioeng. 73(4) 2001: 261270.

14. Bailey CG, Tait AS, Sunstrom NA. High-Throughput Clonal Selection of Recombinant CHO Cells Using a Dominant Selectable and Amplifiable Metallothionein-GFP Fusion Protein. Biotechnol. Bioeng. 80(6) 2002: 670676.

15. Bebbington CR, et al. High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene As an Amplifiable Selectable Marker. Biotechnol. (NY) 10(2) 1992: 169175.

16. Fussenegger M, et al. Controlled Proliferation By Multigene Metabolic Engineering Enhances the Productivity of Chinese Hamster Ovary Cells. Nat. Biotechnol. 16(5) 1998: 468472.

17. Pitti RM, et al. Molecular and Biological Properties of an Interleukin-1 Receptor Immunoadhesin. Mol. Immunol. 31(17) 1994: 13451351.

18. Clark RG, et al. Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGFBP-3): Effects on the Glycemic and Growth Promoting Activities of rhIGF-1 in the Rat. Growth Regul. 3(1) 1993: 5052.

19. Pelletier AJ, et al. Signal Transduction By the Platelet Integrin Alpha IIb Beta 3: Induction of Calcium Oscillations Required for Protein-Tyrosine Phosphorylation and Ligand-Induced Spreading of Stably Transfected Cells. Mol. Biol. Cell 3(9) 1992: 989998.

20. Jordan I, et al. An Avian Cell Line for Production of Highly Attenuated Viral Vectors. 20th Meeting of the European Society for Animal Cell Technology, 1720 June 2007, Dresden, Germany. European Society for Animal Cell Technology: Geneva, Switzerland; www.esact.org.

21. Bailey CG, Tait AS, Sunstrom NA. High-Throughput Clonal Selection of Recombinant CHO Cells Using a Dominant Selectable and Amplifiable Metallothionein-GFP Fusion Protein. Biotechnol. Bioeng. 80(6) 2002: 670676.

22. Chu L, Robinson D. Industrial Choices for Protein Production By Large-Scale Cell Culture. Curr. Opin. Biotechnol. 12(2) 2001: 180187.

23. Grillari J, et al. Analysis of Alterations in Gene Expression After Amplification of Recombinant Genes in CHO Cells. J. Biotechnol. 87(1) 2001: 5965.

24. Senger RS, Karim MN: Effect of Shear Stress on Intrinsic CHO Culture State and Glycosylation of Recombinant Tissue-Type Plasminogen Activator Protein. Biotechnol. Prog. 19: 11991209.

25. Jones D, et al. High-Level Expression of Recombinant IgG in the Human Cell Line PER.C6. Biotechnol. Prog. 19(1) 2003: 163168.

26. Nichols WW, et al. Propagation of Adenoviral Vectors: Use of PER.C6 Cells. Adenoviral Vectors for Gene Therapy. Curiel DT, Douglas JT, eds. Academic Press: New York, NY, 2002: 129166.

27. Bout A. PER.C6 for Protein Production. Williamsburg Bioprocessing Conference, 1519 March 2004, Amsterdam, The Netherlands. Williamsburg Bioprocessing Foundation: Virginia Beach, VA; www.wilbio.com.

28. Crowley J, et al. Process Optimization of the Human Cell Line PER.C6 for the Production of Biopharmacueticals. Cell Culture Engineering IX, 712 March 2004, Cancun, Mexico. Engineering Conferences International: Brooklyn, NY; www.engconfintl.org.

29. Fussenegger M, Bailey JE. Molecular Regulation of Cell-Cycle Progression and Apoptosis in Mammalian Cells: Implications for Biotechnology. Biotechnol. Prog. 14(6) 1998: 807833.

30. Fux C, et al. Streptogramin- and Tetracycline-Responsive Dual Regulated Expression of p27(Kip1) Sense and Antisense Enables Positive and Negative Growth Control of Chinese Hamster Ovary Cells. Nucl. Acids Res. 29(4) 2001: E19.

31. Bi JX, Shuttleworth J, Al R. Uncoupling of Cell Growth and Proliferation Results in Enhancement of Productivity in p21CIP1-Arrested CHO Cells. Biotechnol. Bioeng. 85(7) 2004: 741749.

32. Figueroa J, et al. A Comparison of the Properties of a Bcl-xL Variant to the Wild-Type Anti-Apoptosis Inhibitor in Mammalian Cell Cultures. Metabolic Eng. 5(4) 2003: 230245.

33. Ishaque A, Al R. Role of Ca2+, Mg2+ and K+ Ions in Determining Apoptosis and Extent of Suppression Afforded By bcl-2 During Hybridoma Cell Culture. Apoptosis 4(5) 1999: 335355.

34. Ishaque A, Al R. Role of Vitamins in Determining Apoptosis and Extent of Suppression By bcl-2 During Hybridoma Cell Culture. Apoptosis 7(3) 2002: 231239.

35. Ishaque A, Al R. Use of Intracellular pH and Annexin-V Flow Cytometric Assays to Monitor Apoptosis and its Suppression By bcl-2 Over-Expression in Hybridoma Cell Culture. J. Immunol. Meth. 221(12) 1998: 4357.

36. Simpson NH, et al. Bcl-2 Over-Expression Reduces Growth Rate and Prolongs G1 Phase in Continuous Chemostat Cultures of Hybridoma Cells. Biotechnol. Bioeng. 64(2) 1999: 174186.

37. Simpson NH, et al. In Hybridoma Cultures, Deprivation of Any Single Amino Acid Leads to Apoptotic Death, Which Is Suppressed By the Expression of the bcl-2 Gene. Biotechnol. Bioeng. 59(1) 1998: 9098.

38. Kwaks TH, et al. Identification of Anti-Repressor Elements that Confer High and Stable Protein Production in Mammalian Cells. Nat. Biotechnol. 21(5) 2003: 553558.

39. Fukuda Y, Nishikawa S. Matrix Attachment Regions Enhance Transcription of a Downstream Transgene and the Accessibility of Its Promoter Region to Micrococcal Nuclease. Plant Mol. Biol. 51(5) 2003: 665675.

40. Kwaks TH, Otte AP. Employing Epigenetics to Augment the Expression of Therapeutic Proteins in Mammalian Cells. Trends Biotechnol. 24(3) 2006: 137142.

41. Duncan A, Hadlaczky G. Chromosomal Engineering. Curr. Opin. Biotechnol. 18(5) 2007: 420424.

42. Reik A, etal. Enhanced Protein Production By Engineered Zinc Finger Proteins. Biotechnol. Bioeng. 97(5) 2007: 11801189.

43. Fire A, et al. Potent and Specific Genetic Interference By Double-Stranded RNA in Caenorhabditis Elegans. Nature 391(6669): 806811.42.

44. Urnov FD, et al. Highly Efficient Endogenous Human Gene Correction Using Designed Zinc-Finger Nucleases. Nature 435(7042) 2005: 646651.

45. Mori K, et al. Engineering Chinese Hamster Ovary Cells to Maximize Effector Function of Produced Antibodies Using FUT8 siRNA. Biotechnol. Bioeng. 88(7) 2004: 901908.

46. Baker KN, et al. Metabolic Control of Recombinant Protein N-Glycan Processing in NS0 and CHO Cells. Biotechnol. Bioeng. 73(3) 2001: 188202.

47. Zhang F, etal. The Effect of Dissolved Oxygen (DO) Concentration on the Glycosylation of Recombinant Protein Produced By the Insect Cell-Baculovirus Expression System. Biotechnol. Bioeng. 77(2) 2002: 219224.

Jos M. Coco Martin, PhD, is head of research and development in the animal sciences group of Wageningen UR Division Products, PO Box 65, 8200 AB Lelystad, The Netherlands; 31-320-238249, fax 31-320-238668; jose.coco-martin@wur.nl. Michiel M. Harmsen, PhD, is principal scientist in antibody production in the central veterinary institute of Wageningen UR; 31-320-238436, fax 31-320-238961; michiel.harmsen@wur.nl.